The stock of Vical Incorporated (NASDAQ:VICL) hit a new 52-week low and has $2.01 target or 14.00% below today’s $2.34 share price. The 8 months bearish chart indicates high risk for the $20.79 million company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $2.01 price target is reached, the company will be worth $2.91 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 85,143 shares traded hands or 171.65% up from the average. Vical Incorporated (NASDAQ:VICL) has declined 37.37% since April 1, 2016 and is downtrending. It has underperformed by 38.58% the S&P500.
According to Zacks Investment Research, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.”
VICL Company Profile
Vical Incorporated, incorporated on April 30, 1987, researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Firm has approximately four active, independent, or partnered development programs in the areas of infectious disease including a Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, including invasive Aspergillus, which are causes of morbidity and mortality in immunocompromised patients, including transplant recipients, and a completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.